These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 29588152)

  • 1. Generation and characterization of a potent fully human monoclonal antibody against the interleukin-23 receptor.
    Sasaki-Iwaoka H; Ohori M; Imasato A; Taguchi K; Minoura K; Saito T; Kushima K; Imamura E; Kubo S; Furukawa S; Morokata T
    Eur J Pharmacol; 2018 Jun; 828():89-96. PubMed ID: 29588152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AS2762900-00, a potent anti-human IL-23 receptor monoclonal antibody, prevents epidermal hyperplasia in a psoriatic human skin xenograft model.
    Sasaki-Iwaoka H; Taguchi K; Okada Y; Imamura E; Kubo S; Furukawa S; Morokata T
    Eur J Pharmacol; 2019 Jan; 843():190-198. PubMed ID: 30472202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases.
    Elliott M; Benson J; Blank M; Brodmerkel C; Baker D; Sharples KR; Szapary P
    Ann N Y Acad Sci; 2009 Dec; 1182():97-110. PubMed ID: 20074279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders.
    Benson JM; Peritt D; Scallon BJ; Heavner GA; Shealy DJ; Giles-Komar JM; Mascelli MA
    MAbs; 2011; 3(6):535-45. PubMed ID: 22123062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation and Characterization of Mirikizumab, a Humanized Monoclonal Antibody Targeting the p19 Subunit of IL-23.
    Steere B; Beidler C; Martin A; Bright S; Kikly K; Benschop RJ
    J Pharmacol Exp Ther; 2023 Nov; 387(2):180-187. PubMed ID: 37714687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Receptor occupancy and blocking of STAT5 signaling by an anti-IL-7 receptor α antibody in cynomolgus monkeys.
    Kern B; Li W; Bono C; Lee LF; Kraynov E
    Cytometry B Clin Cytom; 2016 Mar; 90(2):191-8. PubMed ID: 25914284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-IL-12/IL-23p40 antibody ameliorates dermatitis and skin barrier dysfunction in mice with imiquimod-induced psoriasis-like dermatitis.
    Takahashi T; Koga Y; Kainoh M
    Eur J Pharmacol; 2018 Jun; 828():26-30. PubMed ID: 29544684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development in the cynomolgus macaque following administration of ustekinumab, a human anti-IL-12/23p40 monoclonal antibody, during pregnancy and lactation.
    Martin PL; Sachs C; Imai N; Tsusaki H; Oneda S; Jiao Q; Treacy G
    Birth Defects Res B Dev Reprod Toxicol; 2010 Oct; 89(5):351-63. PubMed ID: 20540088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cynomolgus monkey model of interleukin-31-induced scratching depicts blockade of human interleukin-31 receptor A by a humanized monoclonal antibody.
    Oyama S; Kitamura H; Kuramochi T; Higuchi Y; Matsushita H; Suzuki T; Goto M; Adachi H; Kasutani K; Sakamoto A; Iwayanagi Y; Kaneko A; Nanami M; Fujii E; Esaki K; Takashima Y; Shimaoka S; Hattori K; Kawabe Y
    Exp Dermatol; 2018 Jan; 27(1):14-21. PubMed ID: 27714851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment.
    Tillack C; Ehmann LM; Friedrich M; Laubender RP; Papay P; Vogelsang H; Stallhofer J; Beigel F; Bedynek A; Wetzke M; Maier H; Koburger M; Wagner J; Glas J; Diegelmann J; Koglin S; Dombrowski Y; Schauber J; Wollenberg A; Brand S
    Gut; 2014 Apr; 63(4):567-77. PubMed ID: 23468464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab.
    Benson JM; Sachs CW; Treacy G; Zhou H; Pendley CE; Brodmerkel CM; Shankar G; Mascelli MA
    Nat Biotechnol; 2011 Jul; 29(7):615-24. PubMed ID: 21747388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fully human anti-interleukin-8 monoclonal antibodies: potential therapeutics for the treatment of inflammatory disease states.
    Yang XD; Corvalan JR; Wang P; Roy CM; Davis CG
    J Leukoc Biol; 1999 Sep; 66(3):401-10. PubMed ID: 10496309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-IL-23 receptor monoclonal antibody prevents CD4
    Imamura E; Taguchi K; Sasaki-Iwaoka H; Kubo S; Furukawa S; Morokata T
    Eur J Pharmacol; 2018 Apr; 824():163-169. PubMed ID: 29391156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys.
    Hart TK; Cook RM; Zia-Amirhosseini P; Minthorn E; Sellers TS; Maleeff BE; Eustis S; Schwartz LW; Tsui P; Appelbaum ER; Martin EC; Bugelski PJ; Herzyk DJ
    J Allergy Clin Immunol; 2001 Aug; 108(2):250-7. PubMed ID: 11496242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural basis for the dual recognition of IL-12 and IL-23 by ustekinumab.
    Luo J; Wu SJ; Lacy ER; Orlovsky Y; Baker A; Teplyakov A; Obmolova G; Heavner GA; Richter HT; Benson J
    J Mol Biol; 2010 Oct; 402(5):797-812. PubMed ID: 20691190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ustekinumab improves psoriasis-related gene expression in noninvolved psoriatic skin without inhibition of the antimicrobial response.
    Baerveldt EM; Onderdijk AJ; Kurek D; Kant M; Florencia EF; Ijpma AS; van der Spek PJ; Bastiaans J; Jansen PA; van Kilsdonk JW; Laman JD; Prens EP
    Br J Dermatol; 2013 May; 168(5):990-8. PubMed ID: 23278632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunization against an IL-6 peptide induces anti-IL-6 antibodies and modulates the Delayed-Type Hypersensitivity reaction in cynomolgus monkeys.
    Desallais L; Bouchez C; Mouhsine H; Moreau G; Ratsimandresy R; Montes M; Do H; Quintin-Colonna F; Zagury JF
    Sci Rep; 2016 Jan; 6():19549. PubMed ID: 26782790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre- and postnatal development in the cynomolgus monkey following administration of ABT-874, a human anti-IL-12/23p40 monoclonal antibody.
    Enright BP; Tornesi B; Weinbauer GF; Blaich G
    Birth Defects Res B Dev Reprod Toxicol; 2012 Dec; 95(6):431-43. PubMed ID: 23212752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Novel vaccines against M. tuberculosis].
    Okada M
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of SA237, a humanized anti-interleukin-6 receptor monoclonal antibody, on pre- and postnatal development in cynomolgus monkey.
    Katagiri R; Ishihara-Hattori K; Frings W; Amano J; Fuchs A; Chiba S
    Birth Defects Res; 2017 Jul; 109(11):843-856. PubMed ID: 28504465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.